- Home
- DGICB vs KALV Comparison
DGICB vs KALV Comparison
Compare DGICB & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICB | KALV |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.0M | 551.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DGICB | KALV |
|---|---|---|
| Price | $17.30 | $15.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.83 |
| AVG Volume (30 Days) | 3.3K | ★ 992.0K |
| Earning Date | 02-19-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | ★ 219.91 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $987,826,105.00 | $1,426,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | $3.46 | $204.16 |
| P/E Ratio | $8.11 | ★ N/A |
| Revenue Growth | ★ 0.89 | N/A |
| 52 Week Low | $13.19 | $7.30 |
| 52 Week High | $20.46 | $17.30 |
Technical Indicators
Market Signals| Indicator | DGICB | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 54.34 |
| Support Level | $15.96 | $15.12 |
| Resistance Level | $17.71 | $16.45 |
| Average True Range (ATR) | 0.32 | 0.90 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 79.80 | 40.79 |
Price Performance
Historical ComparisonAbout DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.